CAF protocol

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: CAF protocol
• 英文别名: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;N,N-bis(2-chloroethyl)-2-oxo-1,3,2λ5-oxazaphosphinan-2-amine;5-fluoro-1H-pyrimidine-2,4-dione
• 化学式: C38H47Cl2FN5O15P
• 分子量: 934.7
• InChiKey: XJXNQKUJADHQNU-GAJHUODUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.09
• 重原子数：
  62
• 可旋转键数：
  10
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  306
• 氢给体数：
  9
• 氢受体数：
  19

文献信息

• Modified immunization vectors
  申请人：Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of Arizona State University

  公开号：US10370679B2

  公开（公告）日：2019-08-06

  The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

  本公开涉及重组载体及其使用方法。在某些实施方案中，重组载体具有免疫原性。
• Methods and compositions relating to P62 for the treatment and prophylaxis of cancer
  申请人：CureLab Oncology, Inc.

  公开号：US10716837B2

  公开（公告）日：2020-07-21

  Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.

  本发明提供了用于预防和治疗癌症的新型 p62 组合物及相关方法。本发明还提供了可提高 p62 抗癌活性的改性 p62 组合物。
• Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer
  申请人：Aventis Pasteur, Ltd.

  公开号：US20040197912A1

  公开（公告）日：2004-10-07

  The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

  本发明涉及一种编码多肽的核酸以及该核酸或多肽在预防和/或治疗癌症中的用途。特别是，本发明涉及改进的载体，用于插入和表达编码肿瘤抗原的外来基因，以用于癌症的免疫治疗。
• Vaccines using high-dose cytokines
  申请人：Sunnybrook and Women's College Health Sciences Center Aventis Pasteur, Ltd.

  公开号：US20040223949A1

  公开（公告）日：2004-11-11

  The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response.

  本发明涉及癌症免疫疗法领域。特别是，疫苗与大剂量细胞因子结合使用，可增强抗肿瘤免疫反应。
• Tumor antigen BFA5 for prevention and / or treatment of cancer
  申请人：Berinstein Neil

  公开号：US20050112099A1

  公开（公告）日：2005-05-26

  The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

  本发明涉及一种编码多肽的核酸以及该核酸或多肽在预防和/或治疗癌症中的用途。特别是，本发明涉及改进的载体，用于插入和表达编码肿瘤抗原的外来基因，以用于癌症的免疫治疗。